Growth Disorders – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：58頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Growth Disorders – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H2 2012', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Disorders. 'Growth Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Growth Disorders.
- A review of the Growth Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Growth Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Growth Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Growth Disorders pipeline depth and focus of Growth Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H2 2012', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Disorders. 'Growth Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Growth Disorders.
- A review of the Growth Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Growth Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Growth Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Growth Disorders pipeline depth and focus of Growth Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Growth Disorders 8
Growth Disorders Therapeutics under Development by Companies 10
Growth Disorders Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Growth Disorders Therapeutics – Products under Development by Companies 17
Growth Disorders Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Growth Disorders Therapeutics Development 19
Novo Nordisk A/S 19
Access Pharmaceuticals, Inc. 20
Biovitrum AB 21
JCR Pharmaceuticals Co., Ltd. 22
Phage Biotechnology Corporation 23
iBio, Inc. 24
USV Limited. 25
DiAthegen, LLC 26
Growth Disorders – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
JR-401S - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Syntropin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Kiobrina - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Genotropin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Increlex - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Growth Hormone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CobOral hGH - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Recombinant Human Growth Hormone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Somatropin For Injection - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HM10560A - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NN8640 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Growth Factor - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Growth Disorders Therapeutics – Drug Profile Updates 48
Growth Disorders Therapeutics – Discontinued Products 50
Growth Disorders Therapeutics - Dormant Products 51
Growth Disorders – Product Development Milestones 52
Featured News & Press Releases 52
Feb 16, 2012: BioMarin Initiates Phase I Trial For BMN-111 For Treatment Of Achondroplasia 52
Jan 03, 2012: BioMarin To Initiate Phase I Trial In BMN-111 For Treatment Of Achondroplasia 52
Oct 24, 2011: HanAll BioPharma Initiates Phase I Trial Of Vitatropin 52
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency 53
Aug 02, 2011: Swedish Orphan Biovitrum Announces First Patient Enrollment In Kiobrina Phase III Study 53
Jun 15, 2011: Antisense Therapeutics Receives Approval To Commence Phase I Clinical Trial Of ATL1103 54
Jun 09, 2011: ANP Receives Funding To Complete Additional Key Studies On ATL1103 54
May 24, 2011: HanAll BioPharma Receives Grant For HL032 From Korean Government 56
Feb 21, 2011: Antisense Therapeutics Announces Final Preparations For ATL1103 Clinical Trial 56
Oct 18, 2010: HanAll BioPharma Develops Orally Available Human Growth Hormone 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products Under Development for Growth Disorders, H2 2012 8
Products under Development for Growth Disorders – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Novo Nordisk A/S, H2 2012 19
Access Pharmaceuticals, Inc., H2 2012 20
Biovitrum AB, H2 2012 21
JCR Pharmaceuticals Co., Ltd., H2 2012 22
Phage Biotechnology Corporation, H2 2012 23
iBio, Inc., H2 2012 24
USV Limited., H2 2012 25
DiAthegen, LLC, H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Growth Disorders Therapeutics – Drug Profile Updates 48
Growth Disorders Therapeutics – Discontinued Products 50
Growth Disorders Therapeutics – Dormant Products 51
List of Figures
Number of Products under Development for Growth Disorders, H2 2012 8
Products under Development for Growth Disorders – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Growth Disorders 8
Growth Disorders Therapeutics under Development by Companies 10
Growth Disorders Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Growth Disorders Therapeutics – Products under Development by Companies 17
Growth Disorders Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Growth Disorders Therapeutics Development 19
Novo Nordisk A/S 19
Access Pharmaceuticals, Inc. 20
Biovitrum AB 21
JCR Pharmaceuticals Co., Ltd. 22
Phage Biotechnology Corporation 23
iBio, Inc. 24
USV Limited. 25
DiAthegen, LLC 26
Growth Disorders – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
JR-401S - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Syntropin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Kiobrina - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Genotropin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Increlex - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Growth Hormone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CobOral hGH - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Recombinant Human Growth Hormone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Somatropin For Injection - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HM10560A - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NN8640 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Growth Factor - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Growth Disorders Therapeutics – Drug Profile Updates 48
Growth Disorders Therapeutics – Discontinued Products 50
Growth Disorders Therapeutics - Dormant Products 51
Growth Disorders – Product Development Milestones 52
Featured News & Press Releases 52
Feb 16, 2012: BioMarin Initiates Phase I Trial For BMN-111 For Treatment Of Achondroplasia 52
Jan 03, 2012: BioMarin To Initiate Phase I Trial In BMN-111 For Treatment Of Achondroplasia 52
Oct 24, 2011: HanAll BioPharma Initiates Phase I Trial Of Vitatropin 52
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency 53
Aug 02, 2011: Swedish Orphan Biovitrum Announces First Patient Enrollment In Kiobrina Phase III Study 53
Jun 15, 2011: Antisense Therapeutics Receives Approval To Commence Phase I Clinical Trial Of ATL1103 54
Jun 09, 2011: ANP Receives Funding To Complete Additional Key Studies On ATL1103 54
May 24, 2011: HanAll BioPharma Receives Grant For HL032 From Korean Government 56
Feb 21, 2011: Antisense Therapeutics Announces Final Preparations For ATL1103 Clinical Trial 56
Oct 18, 2010: HanAll BioPharma Develops Orally Available Human Growth Hormone 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products Under Development for Growth Disorders, H2 2012 8
Products under Development for Growth Disorders – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Novo Nordisk A/S, H2 2012 19
Access Pharmaceuticals, Inc., H2 2012 20
Biovitrum AB, H2 2012 21
JCR Pharmaceuticals Co., Ltd., H2 2012 22
Phage Biotechnology Corporation, H2 2012 23
iBio, Inc., H2 2012 24
USV Limited., H2 2012 25
DiAthegen, LLC, H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Growth Disorders Therapeutics – Drug Profile Updates 48
Growth Disorders Therapeutics – Discontinued Products 50
Growth Disorders Therapeutics – Dormant Products 51
List of Figures
Number of Products under Development for Growth Disorders, H2 2012 8
Products under Development for Growth Disorders – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31
